Home infusion providers are entering a new phase of growth, but not all specialty therapy lines offer the same strategic opportunity. As legacy infusion categories mature and reimbursement pressures increase, providers and investors are looking to higher-growth specialties that can drive long-term value creation.
In this perspective, we examine the financial and operational potential of expanding into neurology, rare disease, and cardiology. Using predictive financial models, we explore the market dynamics, reimbursement considerations, and growth trajectories shaping each specialty, providing a strategic framework for organizations evaluating where to invest next.
Please complete the form to receive this white paper. Upon submission, the white paper will be sent to your inbox.
Perspective Papers 
Insights 
Webinars 